Bempedoic acid: for whom and when

HIGHLIGHTS

• who: Massimiliano Ruscica from the Department of Pharmacological and Biomolecular Sciences, Universitu00e0 Degli Studi Di Milano, Milan, Italy have published the research work: Bempedoic Acid: for Whom and When, in the Journal: (JOURNAL)
• what: Instead, this was the aim of the openlabel extension (OLE) study that followed the CLEAR Harmony study . This trial has randomized 14,014 patients and will test the superiority of bempedoic acid vs placebo in preventing major cardiovascular events (MACE: cardiovascular death, nonfatal myocardial infarction, nonfatal stroke or coronary revascularization) in patients with (i) established ASCVD or at high risk of . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.